CAR‐T cell‐mediated selective elimination of FRβ+TAMs in the TME results in delayed tumor progression, and prolonged survival in tumor mouse models, highlighting the pro‐tumor role of FRβ+TAMs in the TME and the therapeutic implications of TAM‐depleting agents as preparative adjuncts to conventional immunotherapies that directly target tumor antigens.[82]. Here, FOLR2 is linked to neoplasm.